. Although different forms of cell death characterized by distinct morphological features have long been appreciated, the definitive identification of necroptosis and its involvement in neurological diseases began to be elucidated only about a decade ago, in a study that used small-molecule inhibitors of tumour necrosis factor (TNF)-induced necrosis under apoptosis-deficient conditions 2, 3 . Intensive research on necroptosis in the past decade has led to the elucidation of the molecular mechanisms that underlie the activation of this cell death modality and its pathophysiological importance in human diseases 4, 5 . Necroptosis can be triggered by the activation of death receptors (DRs) such as TNF receptor 1 (TNFR1). Under certain conditions, TNFR1 activation leads to the activation of receptor-interacting protein kinase 1 (RIPK1), and the RIPK1-kinase activity-dependent formation of an RIPK1-RIPK3-mixed lineage kinase domain-like protein (MLKL) complex (also known as complex IIb) (Fig. 1) . Here, the phosphorylation of MLKL by RIPK3 ultimately leads to necroptosis through disruption of the plasma membrane and cell lysis 6 . In addition, the activation of RIPK1 may alternatively lead to apoptosis or neuroinflammation, depending on the cell type and context 4 . In this Review, we provide an overview of the importance of RIPK1 signalling in necroptosis and neuroinflammation in CNS diseases. We briefly describe the role of apoptosis in the developing nervous system and how the adult CNS exhibits reduced sensitivity to intrinsic pathways of apoptosis. We explain how, under pathological conditions, DR-mediated extrinsic cell death pathways may become activated and overcome the resistance of the adult CNS to intrinsic apoptosis, thus promoting both extrinsic apoptosis and necroptosis. Whereas the intrinsic apoptosis pathway is required in normal development, necroptosis is a common deleterious mediator of neurodegeneration. We discuss the role of necroptosis in various neurological diseases and examine how RIPK1 and necroptosis may be activated in specific CNS diseases. Finally, we evaluate evidence suggesting that RIPK1 activity may also contribute to CNS pathology by promoting neuroinflammation and describe the underlying mechanisms. Overall, the activity of RIPK1 has emerged as a central therapeutic target of drug candidates currently being clinically tested for the treatment of neurological diseases 7, 8 .
Apoptosis in the developing CNS An evolutionarily conserved apoptosis programme. Elegant genetic studies in the nematode Caenorhabditis elegans revealed the first insights into the mechanisms of programmed cell death 9 : loss-of-function mutations in the ced-3 and ced-4 genes prevented all apoptosis during nematode development. Strikingly, most of the 131 cells that die during C. elegans development are in the neuronal lineage 10 ; thus, in the developing C. elegans nervous system, apoptosis has a major role in eliminating superfluous neurons and refining neuronal connections.
Death receptors
(DRs). The receptors for tumour necrosis factor (TNF), FAS ligand (FASL) and TNFrelated apoptosis-inducing ligands (TRAiLs) that contain an intracellular protein-protein interaction domain known as the death domain and that can mediate cell death.
Extrinsic cell death
Cell death pathways such as extrinsic apoptosis and necroptosis that are activated upon stimulation of tumour necrosis factor (TNF) receptor 1 (TNFR1), FAS and certain TNF-related apoptosis-inducing ligand (TRAiL) receptors by their cognate ligands. Complex IIa
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases
Complex IIa
RIPK1-independent apoptosis 3

RIPK1-dependent apoptosis 5
Transcription of NF-B response genes Active caspase 8 Caspases, which are the mammalian homologues of cell death protein 3 (CED-3) 11 , mediate neuronal apoptosis in vertebrates, as demonstrated by the finding that, in the chicken dorsal root ganglion, expression of a viral inhibitor of caspases inhibits the neuronal death induced by trophic factor deprivation, a model of developmental neuronal death 12 . Whereas CED-3 controls all of the developmental apoptosis in C. elegans, mammals express 12 different caspases that can regulate apoptosis, as well as certain non-apoptotic functions 13 . Caspases are synthesized as catalytically inactive pro-enzymes consisting of a pro-domain, a large subunit and a small subunit 13, 14 . They may be activated by cell-intrinsic pathways, such as by DNA damage, or by cell-extrinsic pathways -that is, in response to ligands that activate DRs. In the intrinsic pathway of apoptosis, caspase 9 is activated following mitochondrial damage primarily by binding to the cytochrome c-apoptotic protease-activating factor 1 (APAF1) complex, or apoptosome 15 . In the extrinsic pathway of apoptosis, caspases that have a death-effector domain, such as caspase 8, are activated by interacting with signalling complexes downstream of DRs such as TNFR1 and FAS (also known as CD95) 16 . In either case, the activation of initiator caspases by intrinsic or extrinsic pathways leads to further activation of downstream effector caspases, such as caspase 3 and caspase 7 (REF.
17
). Once activated, effector caspases cleave hundreds of molecular substrates, leading to cellular demise 18 .
Apoptosis during nervous system development in mammals. In the nervous system, the intrinsic apoptosis pathway is important for the proper formation of the CNS. Neurons generated during embryonic and early postnatal development are highly sensitive to apoptosis. The survival of immature neurons depends upon trophic factors such as nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) provided by their targeting sites 19 . Trophic factors protect developing neurons by suppressing the mitochondrial pathway of apoptosis, which is mediated by the translocation of BAX from the cytosol to mitochondria, followed by the loss of mitochondrial membrane integrity and caspase activation via apoptosome formation 20 . This formation of the apoptosome promotes the activation of caspase 9 and the downstream caspases such as caspase 3 that are involved in mediating development cell death. Both Casp3 −/− mice 21 and Casp9 −/− mice 22 show similar severe defects in developmental neuronal apoptosis, with marked expansion of the periventricular zone and ectopic cell masses in the CNS, and perinatal lethality. After the proper formation of the CNS, multiple caspases, as well as multiple pro-apoptotic BCL-2 family members, which serve as regulators of mitochondrial apoptosis, are downregulated in the CNS, in part explaining the relative resistance of mature neurons to apoptosis 23, 24 .
Mature neurons show increased resistance to intrinsic apoptosis. Dependence on trophic factors for survival is largely lost once neurons mature (by postnatal day 28 in mice) 25 . Trophic factor withdrawal from cultures of mature sympathetic neurons does not induce apoptosis 20 . Further, adult brain cells are largely refractory to the intrinsic apoptosis induced by mitochondrial damage 26 . This resistance to apoptosis may be an adaptive mechanism to ensure the long-term survival of mature neurons for many decades, as in the human brain. The resistance of mature neurons to apoptosis may be mediated by mechanisms both upstream and downstream of mitochondria in the intrinsic apoptosis pathway [27] [28] [29] .
Overcoming apoptosis resistance of mature neurons. The increased resistance of the adult nervous system to the intrinsic pathway of apoptosis can be overcome under pathological conditions by the activation of the extrinsic apoptosis pathway via the upregulation of the cognate ligands of multiple DRs such as TNF, FAS ligand (FASL) and TNF-related apoptosis-inducing ligand (TRAIL). These DR ligands may be upregulated in the context of chronic neurodegenerative diseases, such as Alzheimer disease (AD), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) [30] [31] [32] [33] [34] [35] [36] , to mediate both cell death and inflammation 37 . Fig. 1 | TNF signalling-mediated apoptosis and necroptosis. The binding of tumour necrosis factor (TNF) to TNF receptor 1 (TNFR1) leads to receptor trimerization and activation. TNFR1-associated death domain (DD) protein (TRADD) and receptorinteracting protein kinase 1 (RIPK1) are recruited to the intracellular DD of activated TNFR1 via their own DDs to initiate the formation of complex I (step 1). In complex I, TRADD recruits the E3 ubiquitin ligases inhibitor of apoptosis 1 (IAP1) and IAP2, which in turn add K63 ubiquitin chains to complex I members, including to the K377 residue of RIPK1. The linear ubiquitylation assembly complex (LUBAC) is recruited by binding with K63 ubiquitin chains in complex I and performs linear (M1) ubiquitylation of RIPK1. The deubiquitylating enzyme CYLD and its adaptor protein spermatogenesis-associated 2 (SPATA2) are recruited together with the LUBAC to complex I. Transforming growth factor-β-activated kinase 1 (TAK1) is recruited to K63 ubiquitin chains on RIPK1 via TAK1-binding protein 2 (TAB2) or TAB3. The nuclear factor-κB (NF-κB) essential modulator (NEMO)-IκB kinase (IKK) complex and the kinase TBK1 are recruited to complex I by binding with M1 ubiquitin chains on RIPK1. M1 ubiquitin-binding proteins such as A20-binding inhibitor of NF-κB activation 1 (ABIN1) and optineurin (OPTN) are also recruited to complex I. ABIN1 in turn recruits the ubiquitin-editing enzyme A20 to complex I. Under normal conditions, activated IKKs and TAK1 lead to NF-κB activation (step 2) and transcription of pro-inflammatory and pro-survival genes, such as those encoding FLICE-inhibitory protein (FLIP) and A20, which suppress the activation of caspase 8 and RIPK1, respectively. When NF-κB activation is inhibited, a cytosolic complex named complex IIa can form to mediate the activation of caspase 8 and subsequent cleavage of RIPK1 and RIPK1-independent apoptosis (step 3). The cleavage of RIPK1 at the carboxyl terminus of its kinase domain (KD) (after residue D324) by caspase 8 provides an important mechanism by which apoptosis, both RIPK1-dependent and RIPK1-independent, may pre-empt the activation of RIPK1 and necroptosis. When caspase 8 activation is blocked, dimerization of RIPK1 via its carboxy-terminal DD leads to RIPK1 activation and formation of complex IIb, which includes FAS-associated DD protein (FADD), caspase 8, RIPK1, RIPK3 and mixed lineage kinase domain-like protein (MLKL). RIPK1 activity is required for the formation of complex IIb (step 4). Pellino 1 (PELI1) mediates K63 ubiquitylation of RIPK1 in complex IIb, promoting the activation of RIPK3 and MLKL to mediate type II necroptosis. Alternatively , when suppression of RIPK1 activity in complex I fails under pathological conditions, RIPK1 may mediate RIPK1-dependent apoptosis (step 5) or type I necroptosis (step 6). Specifically , under IAP1-and IAP2-deficient conditions, or NEMO-, IKK-or TAK1-deficient conditions, an activated, detergent-insoluble ubiquitylated RIPK1 species (iuRIPK1) may form after complex I. iuRIPK1 can accelerate RIPK1 dimerization and the subsequent formation of complex II and RIPK1-dependent apoptosis (step 5). If caspase 8 activation is blocked, the formation of complex IIb, which includes RIPK1, RIPK3 and MLKL , can lead to type I necroptosis (step 6). High levels of activated RIPK1 in complex I and the formation of iuRIPK1 distinguish type I necroptosis from type II necroptosis. Inhibition of RIPK1 kinase by necrostatin-1s (Nec-1s) blocks RIPK1 activation to prevent RIPK1-dependent apoptosis and necroptosis. ID, intermediate domain; TRAF2, TNFR-associated factor 2.
Intrinsic apoptosis
An apoptosis pathway that can be activated upon mitochondrial damage and that activates downstream caspases such as caspase 3.
Whereas the loss of TNFR1 is beneficial in multiple animal models of neurodegenerative diseases, inhibiting more than one DR may have increased benefit. For example, inhibiting both TNF and FASL, through genetic mutations or neutralizing antibodies, is more efficacious in reducing infarct size in the rodent middle cerebral artery occlusion (MCAo) model of stroke than blocking TNF or FASL alone 38 . Similarly, in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, oligodendrocyte loss can be more effectively blocked by inactivating both FAS and TNFR1 than by inhibiting either alone 39 . In addition, in cultured slices of human brain tissue, TRAIL robustly induced apoptosis of neurons, oligodendrocytes, microglia and astrocytes 40 . TRAIL expression is upregulated in the cerebral cortex of individuals with AD, often near plaques of amyloid-β (Aβ) 41 . In chronic and acute human MS lesions, and in mouse brains after induction of EAE, TRAIL is upregulated, predominantly by activated microglia and invading immune cells 42 . Thus, whereas the intrinsic apoptosis pathway is necessary for normal development, the extrinsic apoptosis pathway may serve as a sensor of extracellular inflammatory signalling in the adult nervous system. Moreover, several ligands of the DR family, including TNF, FASL and TRAIL, may cooperate to overcome the resistance of mature neurons to apoptosis by promoting cell death through the extrinsic apoptosis pathway and thus collectively contribute to pathogenesis in neurological disorders. The possible activation of multiple DR family members under disease conditions suggests that therapeutic strategies that can simultaneously target multiple DRs may be more promising than those targeting a single DR.
Necroptosis in neurological diseases
By acting on DRs of various CNS cell types such as neurons and oligodendrocytes, TNF, FASL and TRAIL can induce not only extrinsic apoptosis but also necroptosis through downstream involvement of RIPK1, RIPK3 and MLKL (Fig. 1 ). Necroptosis and RIPK1 have been implicated in many major human CNS diseases (TAbLE 1) . RIPK3-null mice and mice carrying various Ripk1 kinasedead knock-in mutations are normal in development and adult life, demonstrating that, unlike apoptosis, necroptosis is not involved in mediating normal development or adult homeostasis. Strikingly, however, these mutant mice do show resistance in multiple animal models of human inflammatory and neurological diseases (TAbLE 2) .
In the mature nervous system, RIPK1 kinasedependent necroptosis serves as a major executioner of cell death in response to extracellular inflammatory signalling. Necroptosis can be experimentally activated under apoptosis-deficient conditions. Whereas developmental apoptosis is mostly immune silent, necroptosis elicits a strong inflammatory response that can drastically alter the local tissue environment and mediate the pathogenesis of CNS diseases 4, 43 .
Necroptosis induction. The intracellular domains of TNFR1, FAS and TRAIL receptor 1 (TRAILR1) and TRAILR2 all include a death domain (DD) and, following stimulation by their respective cognate ligands, TNF, FASL and TRAIL, they recruit RIPK1 by homotypic binding of their DD to that of RIPK1 (REFS 4, 44 ). Several small-molecule RIPK1 inhibitors have been developed to target the necroptosis activated by multiple members of the DR family (box 1).
Although both FASL and TRAIL can activate necroptosis, their pro-inflammatory activities are considerably weaker than that of TNF 45 . Thus, our discussion here focuses on the downstream pathways activated by TNF, one of the most extensively studied neuroinflammatory cytokines involved in neurodegenerative diseases. TNF can interact with two receptors: TNFR1, which is expressed most prominently by microglia, astrocytes, oligodendrocytes and endothelial cells, and TNFR2, which is predominantly expressed by microglia 46 . Neuronal expression of TNFR1 and TNFR2 is very low under normal conditions 47, 48 . Unlike TNFR1, TNFR2 does not contain the intracellular DD necessary for the formation of complex I (also known as TNF-receptor signalling complex (TNF-RSC)) 49 that is involved in mediating cell death responses; therefore, our discussion here focuses on the signalling pathways mediated by TNFR1 (Fig. 1) .
Stimulation of TNFR1 by TNF leads to the formation of the membrane-associated, intracellular complex I, through the recruitment of two DD-containing proteins, RIPK1 and TNFR1-associated DD protein (TRADD), via homotypic interactions with the TNFR1 DD 50 . In complex I, RIPK1 is subject to several types of ubiquitin modifications, including M1, K11, K48 and K63 ubiquitylation, that have a critical role in modulating the activation of RIPK1 (REF. The activation of RIPK1 represents a key signalling event in the TNFR1 pathway and dictates downstream cell death or survival (Fig. 1 ). RIPK1 activation can lead to cell death by driving the formation of a RIPK1-TRADD-FAS-associated DD protein (FADD)-caspase 8 complex (complex IIa), which triggers caspase activation and leads to RiPK1-dependent apoptosis (RDA) 6 . By contrast, when caspase activity is deficient, RIPK1 activation leads to necroptosis through the formation of a RIPK1-RIPK3-MLKL complex (complex IIb), in which the phosphorylation of MLKL by RIPK3 triggers disruption of the cell membrane and cell lysis [51] [52] [53] [54] (Fig. 3) .
Regulation of RIPK1 activation. The extensive posttranslational modifications of RIPK1 in complex I, including ubiquitylation, deubiquitylation and phosphorylation (Fig. 2) , have a crucial role in deciding whether the cell will live or die and how it might die. Under certain conditions, for example, with deficiency of the E3 ubiquitin ligases inhibitor of apoptosis 1 (IAP1) and IAP2 or of transforming growth factor-β-activated kinase 1 (TAK1), activated, ubiquitylated RIPK1 in complex I can transition to form an insoluble and highly ubiquitylated intermediate complex called iuRIPK1 that can in turn form complex IIa or complex IIb and drive cell death 55 ( Fig. 1) .
In complex I, TRADD recruits the adaptor proteins TNFR-associated factor 2 (TRAF2) or TRAF5 and IAP1 or IAP2, which then catalyse the K63 ubiquitylation of RIPK1 (REF.
56
). K63 ubiquitin chains on RIPK1 promote 
Experimental autoimmune encephalomyelitis
(EAE). An animal model of multiple sclerosis induced by immunizing with purified myelin, peptides from myelinderived proteins or passive transfer of T cells reactive to these myelin proteins.
Immune silent
A state that does not induce immune activation or an inflammatory response.
Death domain (DD)
. A protein-protein interaction module composed of a bundle of six α-helices.
RIPK1-dependent apoptosis
(RDA). RiPK1-dependent activation of caspase 8 and consequent apoptosis, initially triggered by tumour necrosis factor in cells deficient in transforming growth factor-β-activated kinase 1 (TAK1), TbK1 or inhibitor of apoptosis 1 (iAP1) and iAP2. RDA can be inhibited by receptorinteracting protein kinase 1 (RiPK1) inhibitors. Glaucoma RIC protected retinal ganglion cells against ischaemic injury in a rat glaucoma model 164 Retinal ischaemia Nec-1 protected the thickness and histoarchitecture of the inner retina and improved function after retinal ischaemia 165 TNF and RIPK1 were increased in the retinal ganglion cell layer after IR injury. Nec-1 reduced retinal cell loss in IR-injured retinae 166 Nec-1 reduced retinal damage and inflammation after IR injury 167 Retinal detachment Nec-1 attenuated retinal histopathological damage and plasma membrane breakdown in outer retinal layers and improved function after retinal detachment in rats 168 Age-related macular degeneration
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In the degenerative mouse retina, RIPK3 levels were increased. RIPK3 loss protects retinal histoarchitecture and the RPE and prevents inflammation 169 Gaucher disease RIPK3 deficiency increased survival and motor function in a mouse model of Gaucher disease 114 Niemann-Pick disease, type C1 NATuRe RevIewS | NEuRoSCIENCE the recruitment and activation of TAK1, which activates IκB kinases (IKKs) to promote the activation of the nuclear factor-κB (NF-κB) pathway, leading to transcription of pro-survival factors, such as FLICE-inhibitory protein (FLIP), and pro-inflammatory cytokines 57 . Recent evidence suggests that TAK1 can suppress RIPK1 activation either directly through inhibitory phosphorylation or indirectly via activation of downstream kinases including MAPK-activated protein kinase 2 (MK2) and the IKKs [58] [59] [60] [61] . Thus, TAK1 mediates important prosurvival responses by promoting NF-κB-mediated gene transcription and by suppressing RIPK1 activation.
The presence of IAP1 or IAP2 and the K63 ubiquitylation of RIPK1 in complex I also mediates the recruitment of the linear (M1) ubiquitylation assembly complex (LUBAC). LUBAC is composed of haem-oxidized IRP2 ubiquitin ligase 1 (HOIL1), the catalytic subunit HOIL1-interacting protein (HOIP) and shankassociated RH domain-interacting protein (SHARPIN), as well as the deubiquitylating enzyme CYLD and its adaptor spermatogenesis-associated 2 (SPATA2), which can disassemble M1 ubiquitylation [62] [63] [64] [65] [66] [67] [68] . The activation of RIPK1 is negatively modulated by its M1 ubiquitylation status 65, 69, 70 . Three ubiquitin-binding proteins that bind predominantly M1 ubiquitin chains, including optineurin (OPTN), NF-κB essential modulator (NEMO) and A20-binding inhibitor of NF-κB activation 1 (ABIN1), all negatively regulate RIPK1 activation [71] [72] [73] [74] [75] [76] [77] . For example, recruitment of NEMO into complex I leads to activation of the IKK complex, which, similar to TAK1 activation, leads to both NF-κB activation and the suppression of RIPK1 activation via inhibitory 59, 78 . In addition, M1 ubiquitylation of RIPK1 in complex I also mediates the recruitment of the kinase TBK1, which leads to phosphorylation of RIPK1 T189, a site important for RIPK1 substrate recognition; thus, phosphorylation of T189 RIPK1 by TBK1 blocks the transphosphorylation of RIPK1 itself, preventing its activation 79 . Recruitment of ABIN1 into complex I facilitates the recruitment of A20 (also known as TNFAIP3), a ubiquitin-editing enzyme that inhibits the activation of RIPK1 (REFS 76,80-82 ) (Fig. 1) . A20 contains an OTU (ovarian tumour) domain that functions as a K63 deubiquitinase of RIPK1 ). A20 deficiency thus promotes necroptosis by activating RIPK1 and its pro-necroptotic partner RIPK3. ABIN1 deficiency also sensitizes to necroptosis: Abin1 −/− mice die during embryonic development (embryonic day 18.5 (E18.5)) owing to massive liver degeneration that can be blocked by the Ripk1 D138N kinase-dead mutation or by RIPK3 deficiency 76 . Interestingly, a genome-wide association study (GWAS) implicated variants of ABIN1 in ALS and schizophrenia 85 . Thus, ABIN1 deficiency might promote the activation of RIPK1 in ALS and possibly in schizophrenia.
Defective activation of caspase 8 in brain disorders.
Caspase inhibition is a prerequisite for susceptibility to necroptosis in most cell types 2 . In several cell lines, caspase inhibition alone promotes the activation of RIPK1 and thus the autocrine production of proinflammatory cytokines and necroptosis 43 . Caspase 8 is the most important caspase that regulates necroptosis: it inhibits necroptosis by proteolytically cleaving RIPK1 after D324 (Fig. 2) , separating the amino-terminal kinase domain from the carboxy-terminal part of the molecule 86 and preventing RIPK1 kinase activation through dimerization via the carboxy-terminal DD 87 . ). Similarly, in the EAE model of MS, levels of fulllength caspase 8 and FLIP L are increased, whereas levels of the active 18 kDa caspase 8 are decreased 92 . FLIP L expression can be induced by NF-κB 93 ; thus, the ongoing inflammatory response in spinal cords and brains of individuals with MS and in mice after induction of EAE might promote FLIP L expression via the NF-κB pathway and thus facilitate necroptosis by blocking caspase 8 activation.
Caspase 8 deficiency may also be involved in AD. Two CASP8 variants, p.K148R and p.I298V, were identified as risk alleles of AD in a GWAS 94 . Both the K148R
Box 1 | Development of small-molecule inhibitors of RIPK1
Receptor-interacting protein kinase 1 (RIPK1) is an important therapeutic target for the treatment of neurodegenerative diseases. Inactivation of RIPK1 by various genetic mutations, including D138N, K45A and ΔG26F27, leads to strong resistance to tumour necrosis factor (TNF) and no other gross phenotype in mouse models [151] [152] [153] [154] . Furthermore, RIPK1 provides a pharmacologically 'druggable' target, as its kinase domain presents a hydrophobic pocket that is highly amenable for specific small-molecule inhibitors 155, 156 . The first small-molecule inhibitors of RIPK1, including necrostatin-1 (Nec-1) and Nec-4, were isolated in a cell-based highthroughput chemical screen for inhibitors of caspase-independent necrosis 2, 3 . An improved analogue of Nec-1, named Nec-1s, is a highly specific inhibitor of both human and murine RIPK1 with excellent blood-brain barrier (BBB) permeability and reasonable oral availability 126 . Because Nec-1 and Nec-1s can effectively inhibit both murine and human RIPK1, they have been used widely to investigate the role of RIPK1 and necroptosis in various cellular and animal models of human diseases.
Nec-1s binds to the hydrophobic pocket between the amino lobe and carboxyl lobe of the RIPK1 kinase domain outside of the ATP-binding site. Through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements, this binding stabilizes RIPK1 in an inactive conformation, known as the DFg-out conformation 3 . Thus, Nec-1s is an excellent example of a type ii kinase inhibitor.
GSK2982772 is a highly specific and potent inhibitor of human RIPK1 that was identified and optimized from hits of
DNA-encoded libraries
157
. GSK2982772 binds the same allosteric lipophilic pocket at the back of the ATP-binding site of the RIPK1 kinase domain as does Nec-4. GSK2982772 demonstrates a species selectivity for inhibition of primate RIPK1 compared with non-primate RIPK1 and is not BBB permeable 157, 158 . GSK2982772 has been advanced into phase IIa clinical trials for the treatment of non-neurological disorders (namely, psoriasis, rheumatoid arthritis and ulcerative colitis).
Denali Therapeutics is advancing a BBB-permeable RIPK1 inhibitor (DNl747) into phase I trials in Alzheimer disease and amyotrophic lateral sclerosis and has another BBB-permeable RIPK1 inhibitor (DNl788) in preclinical development 7 . In addition, Takeda has reported the development of 7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivatives, including compound 22, as a novel class of potent, orally available and BBB-permeable RIPK1 inhibitors 105 . Compound 22 attenuated disease progression in the mouse experimental autoimmune encephalomyelitis model of multiple sclerosis 105 .
DFG-out conformation
The inactive conformation of the T-loop motif of a kinase, such as RiPK1.
Type II kinase inhibitor
A kinase inhibitor that inactivates the kinase by binding a hydrophobic pocket adjacent to the ATP-binding site. Type ii kinase inhibitors are more specific than type i kinase inhibitors, which bind to the ATP-binding pocket itself. NATuRe RevIewS | NEuRoSCIENCE and the I298V variants show a reduced ability to activate caspase 3, a downstream substrate of caspase 8. It will be interesting to examine whether the K148R mutation may affect the activation of caspase 8 by blocking a ubiquitylation site on the enzyme, as caspase 8 is subject to regulation by multiple E3 ubiquitin ligases 95 .
DNA-encoded libraries
Necroptosis of oligodendrocytes and axonal degeneration.
Pathological axonal degeneration is frequently observed in patients with neurodegenerative disorders, such as ALS, MS, AD and PD, and contributes substantially to neurological disability [96] [97] [98] . Axonal degeneration may be acutely induced by direct nerve transection in a process known as Wallerian degeneration [99] [100] [101] . In chronic neurodegenerative disorders such as MS and ALS, axons may undergo so-called 'Wallerian-like' degeneration, similar to that of Wallerian degeneration but without affecting cell bodies 96 . Increasing evidence suggests that the degeneration and dysfunction of oligodendrocytes are important mechanisms involved in driving axonal degeneration, such as Wallerian-like degeneration, in neurodegenerative diseases 102 .
Focal inflammatory demyelination and axonal degeneration in the white matter of the brain and spinal cord are key pathological features and the cause of permanent disability for individuals with MS. Inhibiting oligodendrocyte death and promoting their ability to remyelinate are major therapeutic goals for treating MS 103 . Whereas apoptosis of oligodendrocytes occurs in the developing mouse CNS 104 , necroptosis of mature primary rodent oligodendrocytes can occur in vitro in response to TNF and can be inhibited by the RIPK1 inhibitor necrostatin-1s (Nec-1s; also named 7N-1 or 7-Cl-O-Nec-1) or by RIPK3 deficiency 92 . Thus, oligodendrocytes may be intrinsically 'hard-wired' for necroptosis when stimulated by TNF, even without exogenous caspase inhibitors. In the cuprizone model of MS, oligodendrocytes undergo rapid degeneration, with concomitant microglial activation and behavioural deficits 92 . RIPK1 inhibition or RIPK3 deficiency reduces motor deficits, myelin loss and microglial activation in the corpus callosum of mice treated with cuprizone 92 . Similarly, the inhibition of RIPK1 by Nec-1s or compound 22 (another RIPK1 inhibitor developed by Takeda) can protect against . The KD is crucial for RIPK1-dependent apoptosis and necroptosis. The cleavage of RIPK1 at D324 by caspase 8 blocks the activation of RIPK1 by separating the KD from the DD, which is critical for mediating RIPK1 activation by dimerization. The autophosphorylation of S14 and/or S15 and S166 of RIPK1 represents biomarkers of its kinase activation. K115 in activated RIPK1 is ubiquitylated by the E3 ubiquitin ligase pellino 1 (PELI1). The kinase TBK1 phosphorylates T189 RIPK1, a residue important for its substrate recognition in autophosphorylation-mediated activation, and thus suppresses its activation. The ID of RIPK1 is involved in regulating nuclear factor-κB (NF-κB) signalling. RIPK1 can be ubiquitylated on multiple residues within this domain; one of these sites, K377 , is a crucial residue that can be ubiquitylated by E3 ubiquitin ligases such as inhibitor of apoptosis 1 (IAP1) or IAP2 and parkin. The K377 residue also serves as a binding hub for downstream signalling, including the NF- 
Wallerian degeneration
The degeneration of a distal axon after a nerve fibre is injured. it is independent of neuronal cell body loss but may contribute to eventual neuronal loss.
Cuprizone model
A rodent model of oligodendrocyte death and reversible demyelination that is induced by feeding with the copper chelator cuprizone.
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demyelination and oligodendrocyte degeneration in EAE animals 92, 105 . ALS affects motor neurons, which have the longest axons of any neurons in the body. Growing evidence suggests that axonal degeneration in ALS may begin early, well before the onset of clinical symptoms 106, 107 , and oligodendrocyte degeneration is a prevalent pathological feature in ALS 97 . One study 75 demonstrated a RIPK1-dependent axonal pathology in mice lacking OPTN (one of the ubiquitin-binding proteins that inhibit RIPK1). These animals exhibited a marked reduction in the number of motor axons and a considerable amount of abnormal myelination in the white matter of the ventrolateral spinal cord, without the loss of motor neuron cell bodies. Moreover, these mice also showed more large-diameter axons and fewer total axons in the ventrolateral white matter, reminiscent of the degeneration and swelling of motor neuron axons in the spinal cords of individuals with early-stage ALS 108 . The motor axons of Optn −/− mice also show ultrastructural evidence of immature myelination with decompaction. Thus, OPTN deficiency leads to the selective axonal degeneration of motor neurons without affecting cell bodies, providing an animal model of Wallerian-like axonal degeneration.
Notably, the axonal degeneration phenotype of Optn −/− mice can be reproduced by the conditional knockout of Optn specifically from oligodendrocytes 75 . Compared with wild-type oligodendrocytes, Optn −/− oligodendrocytes are more sensitive to TNFinduced necroptosis but can be protected by Nec-1s, the Ripk1 D138N kinase-dead mutation or RIPK3 deficiency 75 . Similarly, RIPK1 inhibition and RIPK3 deficiency block axonal degeneration and neural dysfunction in Optn −/− mice. Thus, the loss of OPTN induces the activation of necroptosis of oligodendrocytes that is mediated by RIPK1 and RIPK3, to promote Wallerian-like axonal degeneration.
Extensive degeneration of oligodendrocytes has also been demonstrated in SOD1
G93A mice, a model of ALS in which mice express a mutant form of superoxide dismutase 1 (SOD1) 109 . RIPK1 inhibition and RIPK3 deficiency inhibited axonal myelination defects and delayed the onset of motor dysfunction in SOD1 G93A mice 75 . Thus, necroptosis contributes to the degeneration of oligodendrocytes and motor neuron axons in SOD1 G93A mice. The involvement of necroptosis in ALS may not be limited only to familial ALS: several markers of necroptosis, including levels of insoluble RIPK1, RIPK3, MLKL and phospho-MLKL and increased S14-or S15-phosphorylated RIPK1, were found to be increased in post-mortem spinal cord samples from individuals with sporadic ALS 75 . Although the studies above highlight the role of necroptosis in the degeneration of oligodendrocytes to promote axonal degeneration in a non-cell-autonomous manner, necroptosis may also contribute directly to motor neuron cell death. In a humanized in vitro model of ALS, astrocytes derived from individuals with sporadic ALS, but not from control individuals, killed motor neurons derived from human embryonic stem cells by promoting necroptosis 110 .
Mitochondrial and lysosomal defects promote necroptosis. PD is characterized by progressive loss of dopaminergic neurons in the substantia nigra, and a central role for mitochondrial dysfunction in the aetiology of the disorder has been long established 111 . Recent studies implicate necroptosis in PD and potentially connect mitochondrial defects to necroptosis induction 112 . Similar to the pathology observed in MS, ALS and AD, the protein levels of RIPK1, RIPK3 and MLKL were increased in the post-mortem substantia nigra of individuals with PD compared with controls 112 . Inhibition of RIPK1 kinase activity by necrostatin-1 (Nec-1) protected PC12 cells from cell death induced by 6-hydroxydopamine, a mitochondrial respiration inhibitor used to induce a model of PD 113 , suggesting that RIPK1 activation might be involved in the loss of dopaminergic neurons in PD. Moreover, leucine-rich repeat kinase 2 (LRRK2), which is encoded by a gene often mutated in PD, was identified in a systematic RNAi screen as promoting the activation of complex-I-associated RIPK1 (REF. 55 ). In addition, neural cells differentiated from induced pluripotent stem cells (iPSCs) from patients with PD carrying mutations in the gene encoding optic atrophy 1 (OPA1), a GTPase that regulates mitochondrial fission and fusion, show severe mitochondrial dysfunction and cell death that is inhibited by Nec-1s 112 . Finally, neurotoxicity in the MPTP (1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine)-induced PD mouse model is also attenuated by Nec-1s 112 . These results suggest that mitochondrial dysfunction may sensitize cells to the activation of necroptosis.
PD shares genetic risk factors with Gaucher disease (GD), which is the most common lysosomal storage disease and is caused by mutations in the gene encoding glucocerebrosidase (GBA). In two mouse models of GD, the expression of FLIP is increased and correlates with reductions in caspase 8 activity; furthermore, the expression of both RIPK1 and RIPK3 are elevated 114 . RIPK3 deficiency substantially ameliorated motor function deficits and other symptoms and increased survival in a GBA-inhibitor-induced mouse model of GD 114 . In lysosomal storage diseases, lysosomal stress may promote neuroinflammation, leading to the expression of FLIP, which in turn blocks caspase 8 and allows the induction of necroptosis.
RIPK1 activation and neuroinflammation
In addition to being a key regulator of necroptotic cell death, RIPK1 also promotes neuroinflammation -a parallel deleterious signalling cascade that has emerged as a key driver of neurodegeneration [115] [116] [117] . The risk of neurodegenerative diseases such as AD and ALS is prominently associated with variants of genes in the innate immune system 118 . Understanding the mechanisms by which RIPK1 interacts with these genetic risk factors to promote cell death and inflammation in the CNS should provide important insights into the pathogenesis of human neurodegenerative diseases.
RIPK1-mediated inflammatory responses in microglia. The activation of necroptosis robustly induces a pro-inflammatory gene expression cascade through a RIPK1-mediated, cell-autonomous mechanism 43, 119 . In spinal cords from Optn −/− mice, the levels of proinflammatory cytokines, including interleukin-1α (IL-1α), IL-1β, interferon-γ (IFNγ) and TNF, were all elevated but were reduced by RIPK1 inhibition 75 . The axonal degeneration phenotype of Optn −/− mice can also be mimicked by loss of OPTN specifically from myeloid cells or microglia 75 . Thus, the loss of OPTN from microglia, as well as from oligodendrocytes, can also promote the activation of RIPK1 in microglia and oligodendrocytes to mediate axonal degeneration. RNAsequencing analysis of Optn −/− microglia revealed a module of approximately 1,300 genes -including those encoding pro-inflammatory microglial markers such as the lipopolysaccharide receptor CD14 and CD86 -that were differentially expressed in a RIPK1-dependent manner 75, 120 . OPTN deficiency may therefore promote the activation of pro-inflammatory microglia, which in turn contribute to the myelination and axonal defects.
The RIPK1-mediated inflammatory response in microglia may also contribute to AD. A hallmark of AD is chronic brain inflammation marked by increases in microglial activation and the levels of pro-inflammatory cytokines 121 . A GWAS identified three polymorphisms in the promoter of TNF, two of which are associated with increased TNF production, that are associated with lateonset AD 122 . In addition, individuals with mild cognitive
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www.nature.com/nrn impairment at risk of developing AD show increased cerebrospinal fluid levels of TNF, suggesting that CNS inflammation may occur early in the pathogenesis of AD 31 . In an AD mouse model, deletion of Tnfr1 reduced the production of Aβ, reduced plaque formation and ameliorated the behavioural deficits 123 . The levels of RIPK1 in post-mortem samples from individuals with late-onset AD are increased compared with controls and positively correlate with braak stage 124, 125 . Of the RIPK1-expressing cells identified in human AD brain samples, a considerable fraction resembled microglia and colocalized with the microglial marker ionized calcium-binding adaptor molecule 1 (IBA1) 125 . Moreover, in APP/PS1 mice, a mouse model of AD, increased RIPK1 was found in microglia around Aβ plaques 125 . In the same model, the Ripk1 D138N kinasedead mutation or the RIPK1 inhibitor Nec-1s reduced the number of plaque-associated microglia and the levels of TNF and IL-1β 125, 126 . Necroptosis may also directly contribute to neurodegeneration in mice that express five human familial AD mutations (5xFAD mice) 124 . Another study suggested that Nec-1 may directly alter Aβ aggregation 127 . However, the poor in vivo pharmacodynamics of the original Nec-1 (REF.
126
) used in this study make it difficult to explain how the small molecule could reduce Aβ and tau abnormalities in the CNS and improve behavioural symptoms in the APP/PS1 mouse model 127 . The RIPK1-mediated inflammatory gene signature may be present in multiple neurological diseases and in ageing. The expression of at least eight RIPK1-regulated genes (included Cst7, Clec7a, Csf1 and Ch25h) was differentially affected in 5xFAD mice, SOD1 G93A mice and in ageing microglia 75 . Interestingly, a common variation near the CH25H gene (which encodes cholesterol 25-hydroxylase) was identified as a risk factor for late-onset AD in a GWAS study 128 . CH25H -a cellsurface-bound enzyme -mediates the production of 25-hydroxycholesterol (25-HC). Aberrant production of both CH25H and 25-HC and consequent oligodendrocyte cell death has also been implicated in X-linked adrenoleukodystrophy (X-ALD), a progressive neurodegenerative disorder characterized by cerebral inflammatory demyelination and axonal pathology caused by loss-of-function mutations in the gene encoding ATP-binding cassette transporter subfamily D member 1 (ABCD1) 129 . Interestingly, direct administration of 25-HC into the corpus callosum of wild-type mice leads to local demyelination 129 . Thus, the RIPK1-dependent production of this lipid may represent one of the mechanisms mediating deleterious microglialoligodendrocyte interactions in X-ALD and potentially other neurodegenerative diseases.
Insoluble proteomes in neurodegenerative diseases and necroptosis. As part of the signalling mechanism of necroptosis induction, activated RIPK1 and RIPK3 form amyloid-like fibrils 130 . Whereas most RIPK1, RIPK3 and MLKL in control human brains can be extracted using buffers with no detergent or mild detergent, increased levels of insoluble RIPK1, RIPK3 and MLKL are found in post-mortem pathological samples from individuals with MS, ALS or AD and in animal models of these disorders 75, 92, 125 . Whether this insoluble activated RIPK1 is iuRIPK1 -the form that was recently found to bridge complex I and complex II formation in TNF-induced RDA and a subset of necroptosis 55 -will be an interesting topic to investigate in the future. The formation of insoluble activated RIPK1, RIPK3 and MLKL in human neurodegenerative diseases also raises an intriguing possibility that activation of necroptosis might not only promote necrotic cell death and inflammation but also provide a seeding mechanism for promoting pathological protein aggregation by the formation of insoluble activated RIPK1, RIPK3 and phospho-MLKL oligomers during necroptosis that subsequently mediate neurodegeneration.
Indeed, protein misfolding can also be induced in the corpus callosum of cuprizone-treated mice. This misfolding is reduced by RIPK1 inhibition or RIPK3 deficiency 92 , suggesting that the activation of necroptosis and the RIPK1-mediated inflammatory response can also promote the accumulation of misfolded proteins. Although MS in humans is considered primarily an autoimmune disease, abnormalities of proteostasis have also been reported in the disorder. A quantitative mass spectrometry analysis of the insoluble proteome in MS lesions from human cortex identified a considerable overlap with the proteins associated with Lewy bodies in PD, a classical example of a neurodegenerative disease with inclusion or amyloid pathology 92 . These data suggest that RIPK1 and RIPK3 might promote protein misfolding and aggregation in many neurological and neurodegenerative diseases. Given the increasingly recognized role of inflammation in driving the pathogenesis of MS 131 , the contribution of RIPK1-mediated neuroinflammation to protein aggregation and progressive neurodegeneration should be considered.
Ageing and the onset of necroptosis. Ageing is the most important risk factor for neurodegeneration 132 . In the adipose tissue of aged rodents, the levels of necroptosis markers are increased and correlate with inflammation 133 . Molecular mechanisms that mediate the interaction of ageing with genetic risk factors for neurodegenerative diseases that can promote RIPK1 activation are beginning to be elucidated. Mutations causing haploinsufficiency of TBK1 are a major genetic cause of comorbid ALS and frontotemporal dementia (ALS/FTD), accounting for 10.8% of all cases 134, 135 . A recent study showed that TAK1, a key suppressor of RIPK1 (REF. 58 ), is downregulated in ageing human brains 79 . Reduced expression of TAK1 in myeloid-lineage cells cooperated with the haploid loss of another suppressor of RIPK1, TBK1, in Tbk1 +/− mice, to induce the hallmarks of ALS/ FTD, including neuroinflammation, aggregation of TAR DNA-binding protein 43 (TDP43), axonal degeneration, neuronal loss and behavioural deficits, all of which were blocked upon inhibition of RIPK1 (REF. 79 ). Reduced suppression of RIPK1 kinase activity may represent an important mechanism in ageing human brains that promotes neurological diseases.
The natural decline of proteostasis with ageing may contribute to the onset of neurodegeneration by
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reducing protein turnover, promoting the accumulation of misfolded proteins and enhancing the activation of RIPK1. This age-dependent decline of proteostasis may involve decreases in the stability of correctly folded proteins as well as deficits in protein turnover via autophagy and the proteasome. Autophagy is an important intracellular recycling mechanism through which damaged protein complexes and organelles, including mitochondria, are degraded. Autophagy cargoes are sequestered into autophagosomes, which eventually fuse with lysosomes containing lysosomal proteases that degrade the cargo 136 . A genome-wide small interfering RNA (siRNA) screen identified that ageing of human brains is associated with increases in the expression of autophagy suppressors and decreases in autophagy mediators 137 . The list of genes that were upregulated in ageing brains includes those encoding components of the MAP kinase pathway, which inhibits autophagy. In addition, the expression of the key autophagy genes, such as ATG5, ATG7 and BECN1, were reduced in the aged human brains 137, 138 . In addition to autophagy, proteasomal function also declines during ageing, owing to decreased expression of proteasome subunits, changes in proteasomal function and increased disassembly of proteasomes 139 . Given that chemical inhibition of the proteasome or lysosome alone is sufficient to promote the activation of RIPK1 in microglia 125 , proteostatic decline during ageing may promote the activation of RIPK1.
Activation of RIPK1 drives an increase in microglial expression of an endosomal or lysosomal cathepsin inhibitor known as cystatin F (CST7) 125 . Microglial CST7 expression is strongly induced in several animal models of neurodegenerative diseases, including in SOD1 G93A transgenic mice, a demyelination model and a prion disease model, as well as with ageing [140] [141] [142] . A singlecell RNA-sequencing analysis recently revealed Cst7 to be one of the top biomarkers associated with diseaseassociated microglia in an AD mouse model 143 . In particular, elevated levels of CST7 were found in microglia around Aβ deposits in the APP/PS1 AD mouse model, whereas dispersed microglia were generally negative for CST7. Thus, dysfunction of the lysosomal system in microglia, resulting from increases in CST7, might contribute to reduced proteostasis in AD. Interestingly, inhibition of RIPK1 reduces the microglial expression of CST7 in APP/PS1 mice, suggesting the exciting possibility that an age-associated or disease-associated reduction of lysosomal function in microglial cells may be rescued by blocking the kinase activity of RIPK1 (REF.
125
). Indeed, consistent with this notion, inhibition of RIPK1 reduced the Aβ burden in APP/PS1 mice 125 . Both genetic and pharmacological inhibition of RIPK1 kinase activity enhanced the ability of primary microglia to degrade oligomeric Aβ , consistent with the notion that inflammatory microglia are less proficient at degrading Aβ. These observations suggest that inhibiting RIPK1 activation may promote the ability of microglia to mediate Aβ turnover 125 .
Conclusion
An emerging theme suggests that key mechanisms of neurodegeneration involve the interaction of cellautonomous mechanisms mediated by RIPK1 in CNS glial cells to promote the degeneration of axons and neurons in cell-non-autonomous manners (Fig. 4) . This deleterious environment is established by activated microglia and astrocytes, as well as infiltrating immune cells such as T cells and macrophages 144, 145 , through their ability to release disease-associated inflammatory mediators and promote the vicious cycles of neuroinflammation and neurodegeneration. In this environment, RIPK1 not only may act as a key effector of inflammatory cell death but also may mediate deleterious inflammatory signalling to provide a feedforward mechanism to accelerate neurodegeneration. Microglial receptor-interacting protein kinase 1 (RIPK1) regulates a degenerative neuroinflammatory milieu in the CNS that can lead to necroptosis of oligodendrocytes and axonal degeneration. In neurons, damaged mitochondria and lysosomes can promote necroptosis. In turn, necroptosis can promote inflammation by driving the cell-autonomous expression of pro-inflammatory cytokines, as well as by releasing the cellular content from necrotic cells (including damage-associated molecular patterns (DAMPs)) into the CNS. This deleterious axis creates a progressive inflammatory and degenerative environment in the brain to promote the progression of neurodegenerative disease. MLKL , mixed lineage kinase domain-like protein. 
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Dysregulation of RIPK1 suppression might be important in promoting neuroinflammation and degeneration in the CNS. The activation of RIPK1 is normally suppressed by inhibitory phosphorylation by TAK1, TAK1-activated kinases such as MK2, or TBK1, and by M1 and K48 ubiquitylation (Fig. 2) . Furthermore, activation of the NF-κB pathway under inflammatory conditions may sensitize cells to necroptosis by inducing the expression of FLIP L , which reduces the function of caspase 8 (REF.
146
), the enzyme that normally cleaves and inhibits RIPK1 (REF.
147
). The decline of these RIPK1 suppression mechanisms in ageing and with injury, stress or infection may have important roles in promoting the onset of multiple neurodegenerative diseases.
In contrast to the critical role of RIPK1 kinase activity in mediating RDA, necroptosis and neuroinflammation, the scaffold function of RIPK1 is essential for cell and animal survival, as Ripk1 −/− mice display systemic inflammation and cell death in multiple tissues and die during the postnatal period 91, 148 . Furthermore, rare homozygous loss-of-function RIPK1 mutations in humans lead to immunodeficiency, gut inflammation and progressive polyarthritis 149 . By contrast, blocking RIPK1 kinase activity, as first demonstrated with the small-molecule inhibitors of necroptosis (necrostatins) 2, 3 and subsequently confirmed in multiple lines of kinase-dead RIPK1 knock-in mice (TAbLE 2) and human clinical studies 150 , has no deleterious consequences. Inhibition of RIPK1 kinase confers strong resistance to the TNF-induced systemic inflammatory response [151] [152] [153] . Thus, the kinase activity of RIPK1 may represent an important therapeutic target that can be safely modulated for the treatment of chronic inflammatory CNS diseases by simultaneously inhibiting multiple deleterious mechanisms involved in mediating neurodegeneration.
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